Unlike large biopharma firms, most small biotech companies usually have their fortunes riding on only a single drug. If a small firm’s product fails a Phase II trial, do you think the smart move is to keep working on its product candidate instead of entirely scrapping the project?

Poll Question:
If a firm’s only candidate fails a Phase II trial, should it push on with development?

Yes
25

No
32

Undecided
17

Previous articleThermo Fisher Scientific Purchases Trek Diagnostic Systems
Next articleNabi Stock Plummets as Smoking Cessation Immunotherapy Fails in First Phase III Trial